Enzo Biochem, Inc. ($0.01 Par Value) (ENZ): Price and Financial Metrics

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ): $2.21

0.02 (+0.91%)

POWR Rating

Component Grades













ENZ Stock Summary

  • ENZO BIOCHEM INC's stock had its IPO on January 1, 1986, making it an older stock than 93.22% of US equities in our set.
  • With a year-over-year growth in debt of -32.18%, ENZO BIOCHEM INC's debt growth rate surpasses merely 10.43% of about US stocks.
  • Over the past twelve months, ENZ has reported earnings growth of -636.8%, putting it ahead of just 2.59% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ENZO BIOCHEM INC, a group of peers worth examining would be SWBI, CYAN, ANGI, GOLF, and CNET.
  • Visit ENZ's SEC page to see the company's official filings. To visit the company's web site, go to www.enzo.com.

ENZ Valuation Summary

  • In comparison to the median Healthcare stock, ENZ's EV/EBIT ratio is 273.75% lower, now standing at -13.9.
  • ENZ's EV/EBIT ratio has moved down 46.4 over the prior 243 months.

Below are key valuation metrics over time for ENZ.

Stock Date P/S P/B P/E EV/EBIT
ENZ 2022-09-23 0.9 1.7 -16.0 -13.9
ENZ 2022-09-22 1.0 1.8 -16.7 -14.6
ENZ 2022-09-21 1.0 1.8 -16.8 -14.7
ENZ 2022-09-20 1.0 1.8 -16.9 -14.8
ENZ 2022-09-19 1.1 2.0 -18.7 -16.6
ENZ 2022-09-16 1.2 2.1 -19.8 -17.6

ENZ Growth Metrics

    The 5 year cash and equivalents growth rate now stands at -19.05%.
  • Its year over year revenue growth rate is now at -0.75%.
  • Its year over year net cashflow from operations growth rate is now at -55%.
Over the past 15 months, ENZ's revenue has gone up $15,049,000.

The table below shows ENZ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-03-31 111.6 -7.412 -6.56
2021-12-31 118.175 -4.258 0.3
2021-09-30 115.595 -4.448 5.257
2021-06-30 117.731 0.387 7.875
2021-03-31 112.445 -4.782 1.282
2020-12-31 96.551 -11.216 -10.584

ENZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENZ has a Quality Grade of B, ranking ahead of 78.47% of graded US stocks.
  • ENZ's asset turnover comes in at 1.04 -- ranking 20th of 81 Healthcare stocks.
  • LFMD, RHE, and AHCO are the stocks whose asset turnover ratios are most correlated with ENZ.

The table below shows ENZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-31 1.040 0.455 0.105
2021-04-30 0.996 0.459 0.019
2021-01-31 0.850 0.414 -0.189
2020-10-31 0.736 0.355 -0.371
2020-07-31 0.646 0.313 -0.499
2020-04-30 0.666 0.288 -0.621

ENZ Stock Price Chart Interactive Chart >

Price chart for ENZ

ENZ Price/Volume Stats

Current price $2.21 52-week high $4.15
Prev. close $2.19 52-week low $1.98
Day low $2.21 Volume 10,077
Day high $2.30 Avg. volume 72,821
50-day MA $2.43 Dividend yield N/A
200-day MA $2.73 Market Cap 107.67M

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) Company Bio

Enzo Biochem, Inc. engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is based in New York, New York.

ENZ Latest News Stream

Event/Time News Detail
Loading, please wait...

ENZ Latest Social Stream

Loading social stream, please wait...

View Full ENZ Social Stream

Latest ENZ News From Around the Web

Below are the latest news stories about ENZO BIOCHEM INC that investors may wish to consider to help them evaluate ENZ as an investment opportunity.

Individual investors account for 33% of Enzo Biochem, Inc.'s (NYSE:ENZ) ownership, while institutions account for 27%

Every investor in Enzo Biochem, Inc. ( NYSE:ENZ ) should be aware of the most powerful shareholder groups. And the...

Yahoo | August 30, 2022

Enzo Biochem to Launch Monkeypox Testing Services this Week

NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week. Mr. Hamid Erfanian, Chief Executive Officer of Enzo, stated, “As a leader in testing services for many viral pathogens, Enzo’s clinical labs understands and supports the public health issues posed by monkeypox. We are a

Yahoo | August 11, 2022

Enzo Biochem Appoints Matthew Kupferberg as General Counsel

NEW YORK, NY, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the Company’s in-house General Counsel. Mr. Hamid Erfanian, Chief Executive Officer of Enzo, stated, “We are excited to add someone of Matthew’s caliber to our executive team. After a thorough search, he brings the expertise and proven success in managing the full range of legal business issu

Yahoo | August 3, 2022

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | July 4, 2022

A Enzo Biochem, Inc. (NYSE:ENZ) insider increased their holdings by 21% last year

Looking at Enzo Biochem, Inc.'s ( NYSE:ENZ ) insider transactions over the last year, we can see that insiders were net...

Yahoo | June 11, 2022

Read More 'ENZ' Stories Here

ENZ Price Returns

1-mo -8.68%
3-mo 3.27%
6-mo -24.32%
1-year -37.57%
3-year -36.68%
5-year -78.89%
YTD -31.15%
2021 27.38%
2020 -4.18%
2019 -5.40%
2018 -65.89%
2017 17.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5437 seconds.